top of page

Research

      Our laboratory is dedicated to the exploration of risk assessment, cancer epidemiology, and molecular and genomic epidemiology. Our research is at the forefront of applying epidemiological methodologies in conjunction with cutting-edge technologies to dissect the influence of host factors, viral infections, and environmental elements on the intricate process of cancer development. By uncovering these pivotal risk factors and identifying relevant biomarkers, our research profoundly advances our comprehension of cancer etiology and enables the identification of individuals at elevated risk. We are particularly committed to the development of risk prediction models for various cancers, leveraging these essential biomarkers.
Our research spectrum are as follows:

1. Long-Term Risk Assessment for Obesity, Metabolic Syndrome, and Metabolic-Dysfunction Associated Fatty Liver Disease:

We evaluate the long-term risks associated with hepatic or extrahepatic diseases linked to metabolic dysfunction-related fatty liver disease, a condition that has gained prominence in the context of successful chronic hepatitis virus eradication.

2.   Determinants and Prognostic Factors for Biliary Tract Diseases:

Within this domain, we navigate the determinants and prognostic factors influencing the trajectory of biliary tract diseases. Our aim is to untangle the intricate threads contributing to the onset and progression of these ailments.

3.   Genetic Variants in Cancers and Chronic Diseases:

Our investigation extends to the exploration of genetic variants linked to chronic diseases, spanning liver cancers and neurological disorders. This research seeks to unearth the genetic underpinnings that contribute to disease susceptibility.

4.   Integrating -Omics Information for Gastrointestinal Cancers:

Our lab integrates diverse -omics information to uncover valuable biomarkers associated with gastrointestinal cancers, thus enhancing our capacity to understand and potentially predict these complex diseases.

5.   Host-Virus Interactions in Nasopharyngeal Carcinoma:

We investigate the complex interplay between host and Epstein-Barr virus interactions in nasopharyngeal carcinoma, striving to unravel the mechanisms underpinning the development of this particular cancer.

6.   Evaluating Drug Efficacies on Cancers Using Big Data:

This endeavor focuses on evaluating the efficacy of drugs on various cancers, employing the power of big data to inform our insights. Central to our work is the development of prediction models that intricately weave host genetic markers, environmental risk factors, and virus variants. These models enable us to finely categorize high-risk patients who may require intensive care. Ultimately, the outcomes of our research hold significant promise in shaping prevention and treatment strategies that advance the realm of personalized medicine.

bottom of page